Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 16/20 | 0.51 |
| ▸ | SLC6A4 | P31645 | 12/20 | 0.51 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.51 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.51 |
| ▸ | ABL1 | P00519 | 1/20 | 0.42 |
| ▸ | BCR | P11274 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3941744 | 0.93 | HRH3 (0.59) | HRH3SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL3949031 | 0.88 | HRH3 (0.54) | HRH3SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL4264607 | 0.85 | HRH3 (0.57) | HRH3SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL4012812 | 0.84 | HRH3 (0.58) | HRH3SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL3951317 | 0.83 | VNN1 (0.42) | HRH3SLC6A4 | |
| SCHEMBL4012192 | 0.82 | HRH3 (0.58) | HRH3SLC6A4SLC6A2SLC6A3DRD2 | |
| SCHEMBL4010960 | 0.82 | SLC6A4 (0.74) | HRH3SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL3945117 | 0.81 | SLC6A4 (0.64) | HRH3SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL4014011 | 0.79 | HRH3 (0.42) | HRH3SLC6A4SLC6A2SLC6A3ABL1 | |
| SCHEMBL5013222 | 0.78 | SLC6A4 (0.66) | HRH3SLC6A4SLC6A2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090137562-A1 | SUBSTITUTED BENZYL AMINE COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2009-05-28 | — | — | US | claimed |
| EP-2049473-A2 | SUBSTITUTED BENZYL AMINE COMPOUNDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-04-22 | — | — | EP | claimed |
| US-7479493-B2 | Substituted benzyl amine compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-01-20 | — | — | US | claimed |
| US-20080045509-A1 | SUBSTITUTED BENZYL AMINE COMPOUNDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-02-21 | — | — | US | claimed |
| WO-2008002820-A2 | SUBSTITUTED BENZYL AMINE COMPOUNDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-01-03 | — | — | WO | claimed |
| US-20090137562-A1 | SUBSTITUTED BENZYL AMINE COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2009-05-28 | — | — | US | disclosed |
| US-20090137562-A1 | SUBSTITUTED BENZYL AMINE COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2009-05-28 | — | — | US | disclosed |
| US-20090137562-A1 | SUBSTITUTED BENZYL AMINE COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2009-05-28 | — | — | US | disclosed |
| US-7479493-B2 | Substituted benzyl amine compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-01-20 | — | — | US | disclosed |
| US-7479493-B2 | Substituted benzyl amine compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-01-20 | — | — | US | disclosed |
| US-7479493-B2 | Substituted benzyl amine compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-01-20 | — | — | US | disclosed |
| US-20080045509-A1 | SUBSTITUTED BENZYL AMINE COMPOUNDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-02-21 | — | — | US | disclosed |
| US-20080045509-A1 | SUBSTITUTED BENZYL AMINE COMPOUNDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-02-21 | — | — | US | disclosed |
| US-20080045509-A1 | SUBSTITUTED BENZYL AMINE COMPOUNDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-02-21 | — | — | US | disclosed |
| WO-2008002820-A2 | SUBSTITUTED BENZYL AMINE COMPOUNDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045509-A1 | SUBSTITUTED BENZYL AMINE COMPOUNDS | HRH3, HNMT, HRH4 | HRH3 1/4885SLC6A4 8/4885SLC6A2 17/4885 |
| US-20090137562-A1 | SUBSTITUTED BENZYL AMINE COMPOUNDS | HRH3, HNMT, HRH4 | HRH3 1/4885SLC6A4 8/4885SLC6A2 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.